Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Actoxumab

    go.drugbank.com/drugs/DB16376
    Investigational

    Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

  2. Drug

    Somatrem

    go.drugbank.com/drugs/DB09098
    ApprovedWithdrawn

    these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency [A32292]. … ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be

    Mixtures: Protropin Pws 5mg/vial, Protropin - Kit Im Sc 5mg/vial
  3. Drug

    Bepridil

    go.drugbank.com/drugs/DB01244
    ApprovedWithdrawn

    It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.

  4. Drug

    Bevifimod

    go.drugbank.com/drugs/DB15301
    Investigational

    Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).

  5. Drug

    MK-8189

    go.drugbank.com/drugs/DB19153
    Investigational

    MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).

  6. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...

  7. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy [A34322].

  8. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062] … [A187559] Adagrasib targets KRAS<sup>G12C</sup>, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling.

  9. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

  10. Drug

    Relmapirazin

    go.drugbank.com/drugs/DB19130
    Investigational

    Relmapirazin is under investigation in clinical trial NCT05425719 (Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the Medibeacon Transdermal GFR Measurement System in Evaluation of Kidney Function